Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update

Abstract Objective The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab. Conclusions We revie...

Full description

Saved in:

Bibliographic Details
Published in:	The journal of clinical endocrinology and metabolism Vol. 105; no. 3; pp. 587 - 594
Main Authors:	Shoback, Dolores, Rosen, Clifford J, Black, Dennis M, Cheung, Angela M, Murad, M Hassan, Eastell, Richard
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 01-03-2020
Subjects:	Alendronic acid Antibodies, Monoclonal - therapeutic use Bisphosphonates Bone Density - drug effects Cardiovascular diseases Clinical trials Diagnosis Drug therapy Evaluation Female Fractures Health aspects Humans Monoclonal antibodies Osteoporosis Osteoporosis, Postmenopausal - drug therapy Osteoporotic Fractures - prevention & control Post-menopause Postmenopausal women Practice guidelines (Medicine) Practice Guidelines as Topic - standards Prognosis Societies, Scientific SOST protein United States romosozumab postmenopausal women osteoporosis cardiovascular guideline sclerostin
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Objective The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab. Conclusions We reviewed findings from the meta-analysis and primary clinical trials assessing the efficacy of romosozumab, a monoclonal antibody targeting sclerostin, for the prevention of fractures and concluded that this agent can be considered a treatment option for postmenopausal women at very high risk for osteoporotic fracture. The romosozumab label has a boxed warning, recommending careful consideration by the treating clinician as to cardiovascular risk profile in the individual woman who might receive this agent, since clinical trial data from an active comparator study show an imbalance in serious cardiovascular adverse events between romosozumab and alendronate.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0021-972X 1945-7197
DOI:	10.1210/clinem/dgaa048